2017 Section 7 Green Book

Dove press

Yimaer et al

Table 1 Baseline characteristics of the five trials included for analysis Author (year) Phase Total patients Age (years)

Treatment regimens

No for analysis

FAEs Median PFS (months)

Jadad score

Leboulleux et al 32 (2012)

II

145

63 64

Vandetanib 300 mg qd po 72

2 1 5 2

11.1

5

Placebo

73

5.9

Wells et al 30 (2012)

III

331

50.7 53.4

Vandetanib 300 mg qd po 231

30.5 19.3 11.4

5

Placebo

100

Elisei et al 29 (2013)

III

330

55 55 63 63 64 61

Cabozantinib 140 mg qd po 214

17

5

Placebo

109 207 209 261 131

8

4

Brose et al 31 (2014)

III

416

Sorafenib 400 mg bid po

12

10.8

5

Placebo

6 6 0

5.8

Schlumberger et al 33 (2015)

III

392

Lenvatinib 24 mg qd po

18.3

5

Placebo

3.6

Abbreviations: bid, twice daily; FAEs, fatal adverse events; PFS, progression-free survival.

$

5LVN UDWLR DQG &,

6WXG\ QDPH

6WDWLVWLFV IRU HDFK VWXG\

(YHQWV WRWDO

8SSHU OLPLW

/RZHU OLPLW

*URXS $ *URXS %

5LVN UDWLR

= YDOXH

3 YDOXH

/HERXOOHX[ HW DO :HOOV HW DO (OLVHL HW DO %URVH HW DO 6FKOXPEHUJHU HW DO 3RROHG UHVXOWV

9(*)5 7.,V

3ODFHER

%

6WXG\ QDPH

6WDWLVWLFV IRU HDFK VWXG\

(YHQWV WRWDO

5LVN UDWLR DQG &,

*URXS $ *URXS %

5LVN UDWLR

/RZHU OLPLW

8SSHU OLPLW

= YDOXH

3 YDOXH

/HERXOOHX[ HW DO :HOOV HW DO (OLVHL HW DO %URVH HW DO 6FKOXPEHUJHU HW DO

3RROHG UHVXOWV

9(*)5 7.,V

3ODFHER

&

6WXG\ QDPH

6WDWLVWLFV IRU HDFK VWXG\

(YHQWV WRWDO

5LVN UDWLR DQG &,

5LVN UDWLR

/RZHU OLPLW

8SSHU OLPLW

= YDOXH

3 YDOXH

*URXS $ *URXS %

/HERXOOHX[ HW DO :HOOV HW DO (OLVHL HW DO %URVH HW DO 6FKOXPEHUJHU HW DO

3RROHG UHVXOWV

9(*)5 7.,V

3ODFHER

Figure 2 Risk of severe adverse outcomes associated with VEGFR-TKIs treatment compared with placebo treatment: ( A ) FAEs, ( B ) any severe adverse events, and ( C ) treatment discontinuation. Notes: Group A: VEGFR-TKIs group; Group-B: placebo group. Abbreviations: CI, confidence interval; FAEs, fatal adverse events; VEGFR-TKIs, vascular endothelial growth factor receptor tyrosine kinase inhibitors.

OncoTargets and Therapy 2016:9

submit your manuscript | www.dovepress.com Dove press

178

PoweredbyTCPDF (www.tcpdf.org)